News | March 09, 2022
SII’s Covovax approved for 12-17 years age group
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
The recommendation has been sent to the DCGI for approval
This is the ninth Covid-19 vaccine approved in India
The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The vaccines are currently only authorised for emergency use in the country
However, these won’t be available at the nearest chemist store soon
It has also been granted permission to conduct trials for booster dose
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Subscribe To Our Newsletter & Stay Updated
